How should we assess the effects of exposure to dietary polyphenols in vitro?
Open Access
- 1 July 2004
- journal article
- review article
- Published by Elsevier BV in The American Journal of Clinical Nutrition
- Vol. 80 (1), 15-21
- https://doi.org/10.1093/ajcn/80.1.15
Abstract
Human intervention studies have provided clear evidence that dietary polyphenols (eg, flavonoids—eg, flavonols—and isoflavones) are at least partly absorbed and that they have the potential to exert biological effects. Biological activity of polyphenols is often assessed by using cultured cells as tissue models; in almost all such studies, cells are treated with aglycones or polyphenol-rich extracts (derived from plants and foods), and data are reported at concentrations that elicited a response. There are 2 inherent flaws in such an approach. First, plasma and tissues are not exposed in vivo to polyphenols in these forms. Several human studies have identified the nature of polyphenol conjugates in vivo and have shown that dietary polyphenols undergo extensive modification during first-pass metabolism so that the forms reaching the blood and tissues are, in general, neither aglycones (except for green tea catechins) nor the same as the dietary source. Polyphenols are present as conjugates of glucuronate or sulfate, with or without methylation of the catechol functional group. As a consequence, the polyphenol conjugates are likely to possess different biological properties and distribution patterns within tissues and cells than do polyphenol aglycones. Although deconjugation can potentially occur in vivo to produce aglycone, it occurs only at certain sites. Second, the polyphenol concentrations tested should be of the same order as the maximum plasma concentrations attained after a polyphenol-rich meal, which are in the range of 0.1–10 μmol/L. For correct interpretation of results, future efforts to define biological activities of polyphenols must make use of the available data concerning bioavailability and metabolism in humans.Keywords
This publication has 62 references indexed in Scilit:
- Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juiceEuropean Journal of Clinical Nutrition, 2003
- Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathwayBiochemical and Biophysical Research Communications, 2002
- Metabolism of quercetin and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in human plasmaXenobiotica, 2002
- Pharmacokinetics and Bioavailability of Quercetin Glycosides in HumansThe Journal of Clinical Pharmacology, 2001
- Protection by quercetin and quercetin 3-O-β-D-glucuronide of peroxynitrite-induced antioxidant consumption in human plasma low-density lipoproteinFree Radical Research, 2001
- Flavonol–serum albumin complexation. Two-electron oxidation of flavonols and their complexes with serum albuminJournal of the Chemical Society, Perkin Transactions 2, 1999
- Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β‐glucosidase activityFEBS Letters, 1998
- Survey of the Free and Conjugated Myricetin and Quercetin Content of Red Wines of Different Geographical OriginsJournal of Agricultural and Food Chemistry, 1998
- Bioavailability of flavonoids from teaCritical Reviews in Food Science and Nutrition, 1997
- Bioavailability of the dietary antioxidant flavonol quercetin in manCancer Letters, 1997